No Data
No Data
Express News | Indaptus Therapeutics- Combined Effective Purchase Price for Each Share & Warrants Is $1.065
12 Health Care Stocks Moving In Monday's Pre-Market Session
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
Indaptus Therapeutics Announces Anticipated Milestones in 1H of 2025
Express News | Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Indaptus Therapeutics Plans 1.94 Million Secondary Share Offering